What's Rubicon Research Ltd share price today. Get Rubicon Research Ltd latest news on BSE/NSE stock price live updates, Rubicon Research Ltd financial results and overview, Rubicon Research Ltd stock ...

Rubicon Research Private Limited, a a portfolio company of General Atlantic, has acquired Concord, Ontario-based Impopharma, a development and testing facility specializing in pulmonary and nasal drug ...

MUMBAI, India--(BUSINESS WIRE)--As part of its ongoing effort to establish a global development network, Rubicon Research Private Limited, a leading specialty pharmaceutical company, today announced ...

Rubicon Research IPO: Following the conclusion of bidding for the initial public offering (IPO) of Rubicon Research Limited, attention has shifted to the Rubicon Research IPO allotment date, which is ...

Rubicon Research’s Rs 1,377 crore IPO has entered its third and final day of bidding. By the end of Day 2, the issue was subscribed 2.37 times, driven largely by robust retail demand, which saw ...

PALO ALTO, Calif., April 21, 2026--(BUSINESS WIRE)--GEn1E Lifesciences Inc., a Phase 2 clinical-stage biotechnology company advancing AI-driven novel precision medicines for immunology, inflammation, ...

Mumbai: Rubicon Research has moved swiftly from announcement to execution, finalizing its majority stake acquisition in Arinna Lifesciences within just over two weeks, signaling a strong intent to ...

Rubicon Research Private Limited, a leading specialty pharmaceutical company, announced the acquisition of Meditab Specialities Limited’s oral liquid dosage and nasal product manufacturing facility ...

Everstone, a private equity firm specializing in India and Southeast Asia, has finally decided to shell out Rs 220 crore ($33 million) to obtain a 70% stake--a much larger piece of the pie than ...

ANN ARBOR, Mich., Jan. 12 /PRNewswire/ -- Rubicon Genomics today announced a licensing agreement with Abbott, which marks the achievement of significant milestones within their on-going Research and ...

GEn1E Lifesciences Inc., a Phase 2 clinical-stage biotechnology company advancing AI-driven novel precision medicines for immunology, inflammation, and rare diseases, today announced a strategic ...